The prevention of type 2 diabetes

Nature Clinical Practice Endocrinology and Metabolism

Volumn 4, Issue 7, 2008, Pages 382-393

  Crandall, Jill P ^a   Knowler, William C ^b   Kahn, Steven E ^c   Marrero, David ^d   Florez, Jose C ^e   Bray, George A ^f   Haffner, Steven M ^g   Hoskin, Mary ^h   Nathan, David M ⁱ  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d INDIANA UNIVERSITY   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f LOUISIANA STATE UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h Digestive and Kidney Diseases   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Impaired glucose tolerance; Prediabetes; Prevention; Type 2 diabetes

Indexed keywords

ACARBOSE; EXENDIN 4; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PHENFORMIN; PLACEBO; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TOLBUTAMIDE; TROGLITAZONE;

BARIATRIC SURGERY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIET RESTRICTION; DRUG COST; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EDEMA; EXERCISE; GASTROINTESTINAL SYMPTOM; GENETIC RISK; HIGH FIBER DIET; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PREDIABETIC STATE;

EID: 45849132668     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0843     Document Type: Review

References (99)

1. Centers for Disease Control and Prevention (2005) National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention
2. Jensen CC et al. (2002) Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes 51: 2170-2178
3. Weyer C et al. (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104: 787-794
4. Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19
5. Jarrett RJ et al. (1979) Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia 16: 25-30
6. Knowler WC et al. (1995) Preventing non-insulin-dependent diabetes. Diabetes 44: 483-488
7. Keen H et al. (1982) The ten-year follow-up of the Bedford survey (1962-1972): glucose tolerance and diabetes. Diabetologia 22: 73-78
8. Sartor G et al. (1980) Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29: 41-49
9. Knowler WC et al. (1997) Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 40: 680-686
10. Goede P et al. (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591
11. Nathan DM et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653
12. Norris SL et al. (2005) Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No.: CD005270. doi:10.1002/14651858.CD005270
13. Pan XR et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544
14. Tuomilehto J et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350
15. Laaksonen DE et al. (2005) Physical activity in the prevention of type 2 diabetes: the Finnish diabetes prevention study. Diabetes 54: 158-165
16. Lindström J et al. (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368: 1673-1679
17. The Diabetes Prevention Program Research Group (1999) Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22: 623-634
18. The Diabetes Prevention Program Research Group (2000) Baseline characteristics of the randomized cohort. Diabetes Care 23: 1619-1629
19. Knowler WC et al. for the Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403
20. Hamman RF et al. (2006) Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29: 2102-2107
21. The Diabetes Prevention Program Research Group (2006) The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes. J Gerontol A Biol Sci Med Sci 61: 1075-1081
22. Kosaka K et al. (2005) Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 67: 152-162
23. Ramachandran A et al. (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49: 289-297
24. Pories WJ et al. (1992) Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 215: 633-642
25. Pories WJ et al. (1992) Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 55 (Suppl): S582-S585
26. Pories WJ et al. (1995) Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222: 339-350
27. Long SD et al. (1994) Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: a longitudinal interventional study. Diabetes Care 17: 372-375
28. Sjöström L et al. (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683-2693
29. Sjöström L (2004) Surgical treatment of obesity: an overview of the results from the SOS study. In Handbook of Obesity: Clinical applications (Eds GA Bray and C Bouchard) New York: Marcel Dekker
30. Dixon AF et al. (2005) Laparoscopic adjustable gastric banding induces prolonged satiety: a randomized blind crossover study. J Clin Endocrinol Metab 90: 813-819
31. Dixon JB et al. (2008) Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299: 316-323
32. Mari A et al. (2006) Restoration of normal glucose tolerance in severely obese patients after biliopancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 49: 2136-2143
33. Rubino F et al. (2004) The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240: 236-242
34. Gillies CL et al. (2007) Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334: 299
35. Walker EA et al. (2006) Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29: 1997-2002
36. The Diabetes Prevention Program Research Group (2007) Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes 56: 1153-1159
37. Yang W et al. (2001) The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 17: 131-136
38. Buchanan TA et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796-2803
39. The Diabetes Prevention Program Research Group (2005) Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54: 1150-1156
40. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators, Gerstein HC et al. (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368: 1096-1105
41. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471
42. Kahn SE et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443
43. American Diabetes Association (2004) Prevention or delay of type 2 diabetes. Diabetes Care 27 (Suppl 1): S47-S54
44. Nathan DM and Berkwits M (2007) Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. Ann Intern Med 146: 461-463
45. Holman RR et al. (2007) Results from the early diabetes intervention trials [abstract]. Diabetes 52 (Suppl 1): A16
46. Pan CY et al. (2003) Efficacy of acarbose in Chinese subjects with impaired glucose tolerance. Diabetes Res Clin Pract 61: 183-190
47. Chiasson JL et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072-2077
48. Torgerson JS et al. (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27: 155-161
49. Heymsfield SB et al. (2000) Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 160: 1321-1326
50. Yusuf S et al. (2001) Ramipril and the development of diabetes. JAMA 286: 1882-1885
51. DREAM trial investigators, Bosch J et al. (2006) Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551-1562
52. Freeman DJ et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103: 357-362
53. Collins R et al. (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016
54. Keech A et al. (2003) Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 26: 2713-2721
55. Sever PS et al. (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 64 (Suppl 2): 43-60
56. Meece J (2007) Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin 23: 933-944
57. The Diabetes Prevention Program Research Group (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54: 2404-2414
58. The Diabetes Prevention Program Research Group (2003) Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26: 977-980
59. Chiasson JL et al. (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 290: 486-494
60. The Diabetes Prevention Program Research Group (2005) Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 28: 888-894
61. The Diabetes Prevention Program Research Group (2005) Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54: 1566-1572
62. The Diabetes Prevention Program Research Group (2005) The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 142: 611-619
63. Carnethon MR et al. for the Diabetes Prevention Program Research Group (2006) The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care 29: 914-919
64. Hämäläinen H et al. (2005) Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetologia 48: 2248-2253
65. Florez JC et al. (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355: 241-250
66. Wang J et al. (2007) Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion. Diabetologia 50: 1192-1200
67. Lyssenko V et al. (2005) Genetic prediction of future type 2 diabetes. PLoS Med 2: e345
68. Laukkanen O et al. (2004) Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89: 6286-6290
69. The Diabetes Prevention Program Research Group (2007) Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 92: 1502-1509
70. Florez JC et al. (2007) Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 56: 531-536
71. Satterfield DW et al. (2003) Community-based lifestyle interventions to prevent type 2 diabetes. Diabetes Care 26: 2643-2652
72. Cook VV and Hurley JS (1998) Prevention of type 2 diabetes in childhood. Clin Pediatr (Phila) 37: 123-129
73. Engelgau MM et al. (1998) A project to reduce the burden of diabetes in the African-American community: project DIRECT. J Natl Med Assoc 90: 605-613
74. Holcomb JD et al. (1998) Evaluation of Jump Into Action: a program to reduce the risk of non-insulin dependent diabetes mellitus in school children on the Texas-Mexico border. J Sch Health 68: 282-288
75. Marlow E et al. (1998) STOP diabetes! An educational model for Native American adolescents in the prevention of diabetes. Diabetes Educ 24: 441-450
76. Mau MK et al. (2001) Mediators of lifestyle behavior change in native Hawaiians: initial findings from the Native Hawaiian Diabetes Intervention Program. Diabetes Care 24: 1770-1775
77. Narayan KM et al. (1998) Randomized clinical trial of lifestyle interventions in Pima Indians: a pilot study. Diabet Med 15: 66-72
78. Teufel NI and Ritenbaugh CK (1998) Development of a primary prevention program: insight gained in the Zuni Diabetes Prevention Program. Clin Pediatr (Phila) 37: 131-141
79. Trevino RP et al. (1998) Bienestar: a diabetes risk-factor prevention program. J Sch Health 68: 62-67
80. Ackermann RT et al. (2007) Translating the Diabetes Prevention Program into the community: the YMCA model [abstract]. Diabetes 67 (Suppl 1): A42
81. Ackermann RT and Marrero DG (2007) Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ 33: 69-78
82. Ratner R (2004) Community-based identification of pre-diabetes: efficient screening techniques for implementation of diabetes prevention strategies [abstract]. Diabetes 61 (Suppl 1): A290
83. Seidel MC et al. (2007) Translating the Diabetes Prevention Program (DPP) in an urban underserved community: long term sustainability of positive clinical outcomes [abstract]. Diabetes 67 (Suppl 1): A42
84. Bjärås G et al. (2001) Walking campaign: a model for developing participation in physical activity? Experiences from three campaign periods of the Stockholm Diabetes Prevention Program (SDPP). Patient Educ Couns 42: 9-14
85. Daniel M et al. (1999) Effectiveness of community-directed diabetes prevention and control in a rural Aboriginal population in British Columbia, Canada. Soc Sci Med 48: 815-832
86. Rowley KG et al. (2000) Reduced prevalence of impaired glucose tolerance and no change in prevalence of diabetes despite increasing BMI among Aboriginal people from a group of remote homeland communities. Diabetes Care 23: 898-904
87. Simmons D et al. (1996) A pilot diabetes awareness and exercise programme in a multiethnic workforce. NZ Med J 109: 373-376
88. Simmons D et al. (1998) A pilot urban church-based programme to reduce risk factors for diabetes among Western Samoans in New Zealand. Diabet Med 15: 136-142
89. Saaristo T et al. (2007) National type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health 66: 101-112
90. Herman WH et al. for the Diabetes Prevention Program Research Group (2005) The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142: 323-332
91. Eddy DM et al. (2005) Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143: 251-264
92. Engelgau MM (2005) Trying to predict the future for people with diabetes: a tough but important task. Ann Intern Med 143: 301-302
93. Ramachandran A et al. (2007) Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 30: 2548-2552
94. Vijgen SM et al. (2006) Cost effectiveness of preventive interventions in type 2 diabetes mellitus: a systematic literature review. Pharmacoeconomics 24: 425-441
95. American Diabetes Association (2008) Standards of medical care in diabetes - 2008. Diabetes Care 31 (Suppl 1): S12-S54
96. Nathan DM et al. (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30: 753-759
97. Edelstein SL et al. (1997) Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46: 701-710
98. Stern MP et al. (2002) Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136: 575-581
99. Wilson PW et al. (2007) Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 167: 1068-1074